Drug profile · INN
hydrocortisone probutate
PANDEL
hydrocortisone probutate (PANDEL) is a glucocorticoid receptor agonist. Route of administration: topical. Current US regulatory status: approved.
Drug details — hydrocortisone probutate
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
hydrocortisone probutate (PANDEL) is a glucocorticoid receptor agonist. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Glucocorticoid receptor agonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is hydrocortisone probutate?
hydrocortisone probutate (PANDEL) is a glucocorticoid receptor agonist. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for hydrocortisone probutate?
PANDEL is a marketed brand name for hydrocortisone probutate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of hydrocortisone probutate?
hydrocortisone probutate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.